Rallybio Corp (RLYB) — SEC Filings
Rallybio Corp (RLYB) — 29 SEC filings. Latest: 8-K (May 4, 2026). Includes 13 8-K, 6 10-Q, 5 SC 13G/A.
View Rallybio Corp on SEC EDGAR
Overview
Rallybio Corp (RLYB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Rallybio Corp (RLYB) reported a net income of $16.016 million for the three months ended September 30, 2025, a significant improvement from a net loss of $11.466 million in the same period last year. This turnaround was primarily driven by a substantial gain of $22.479 million from the sale of a joi
Sentiment Summary
Across 29 filings, the sentiment breakdown is: 3 bearish, 24 neutral, 2 mixed. The dominant filing sentiment for Rallybio Corp is neutral.
Filing Type Overview
Rallybio Corp (RLYB) has filed 13 8-K, 6 10-Q, 2 DEF 14A, 5 SC 13G/A, 1 SC 13G, 1 10-K, 1 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (29)
Risk Profile
Risk Assessment: Of RLYB's 22 recent filings, 4 were flagged as high-risk, 9 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $636K |
| Net Income | $16.016M |
| EPS | $0.36 |
| Debt-to-Equity | 0.07 |
| Cash Position | $59.3M |
| Operating Margin | -100.0% |
| Total Assets | $67.661M |
| Total Debt | $4.627M |
Key Executives
- David M. Gryska
- Sarah E. P. Johnson
- Dr. Jeffrey M. Chiodo
- Dr. Sarah L. Boyce
- Wendy K. Chung
- Robert Hopfner
- Ronald Hunt
- Hui Liu
- Abigail P. Johnson
Industry Context
Rallybio operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing therapies for rare diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, robust clinical trial data, and effective capital management to navigate the path from discovery to market approval.
Top Tags
10-Q (4) · financials (4) · biotech (4) · Biotechnology (3) · corporate-governance (3) · Rallybio Corp (3) · amendment (3) · delisting (2) · compliance (2) · SEC Filing (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net income for Q3 2025 | $16.016M | Significant improvement from a $11.466M net loss in Q3 2024, driven by JV sale. |
| Gain on sale of joint venture | $22.479M | Primary driver of Q3 2025 net income. |
| Net loss for nine months ended Sept 30, 2025 | $3.126M | Reduced from $46.731M loss in prior year, aided by JV sale. |
| Research and development expenses for Q3 2025 | $4.143M | Decreased from $8.240M in Q3 2024, reflecting program discontinuation. |
| Research and development expenses for nine months ended Sept 30, 2025 | $15.942M | Decreased from $34.122M in prior year, reflecting program discontinuation. |
| Cash, cash equivalents, and marketable securities | $59.3M | Total liquidity as of September 30, 2025, providing operational runway. |
| Shares of common stock outstanding | 42,243,774 | As of October 31, 2025. |
| Collaboration and License Revenue | $0 | for the three and six months ended June 30, 2025, indicating no current income |
| Additional Paid-In Capital | $173,941,000 | as of June 30, 2025, representing capital raised from investors |
| Retained Earnings | -$173,941,000 | as of June 30, 2025, reflecting accumulated losses |
| Common Stock | $1,000 | as of June 30, 2025, remaining stable |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
| Filing Date | 2025-05-08 | Shows when the 10-Q was officially submitted to the SEC. |
| Report Date | 20250313 | Date of earliest event reported |
| Fiscal Year End | 1231 | Indicates the end of the company's financial year |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, but potentially fluctuating, stake in Rallybio Corp.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"medium"}
- {"claim":"Rallybio Corp's stock price will experience some stability due to continued institutional interest.","entity":"Rallybio Corp","targetDate":"2024-08-09","confidence":"low"}
Frequently Asked Questions
What are the latest SEC filings for Rallybio Corp (RLYB)?
Rallybio Corp has 29 recent SEC filings from Jan 2024 to May 2026, including 13 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RLYB filings?
Across 29 filings, the sentiment breakdown is: 3 bearish, 24 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Rallybio Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Rallybio Corp (RLYB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Rallybio Corp?
Key financial highlights from Rallybio Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RLYB?
The investment thesis for RLYB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Rallybio Corp?
Key executives identified across Rallybio Corp's filings include David M. Gryska, Sarah E. P. Johnson, Dr. Jeffrey M. Chiodo, Dr. Sarah L. Boyce, Wendy K. Chung and 4 others.
What are the main risk factors for Rallybio Corp stock?
Of RLYB's 22 assessed filings, 4 were flagged high-risk, 9 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Rallybio Corp?
Recent forward-looking statements from Rallybio Corp include guidance on {"claim":"FMR LLC will maintain a significant, but potentially fluctuating, stake in Rallybio Corp.","entity":"FMR LLC", and 1 other predictions.